Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Alexion | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Alexion

Strensiq launched in the quarter, Soliris sales up 15%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Alexion

4Q Revenues: $701 million (-17%)
 
4Q Earnings: $66.6 million (-57%)
 
FY Revenues: $2.6 billion (+21%)
 
FY Earnings: $144.4 million (earnings were $657 million FY14)
 
Comments: Soliris sales were $689 million in the quarter, up 15%. For the year, Soliris sales were $2.6 billion, up 21%. Strensiq sales were $11.6 million in the quarter and $12 million for the year. Strensiq was approved by the FDA for the treatment of perinatal-, infantile- and juvenile-onset hypophosphatasia (HPP) in 4Q15. R&D expenses were $191 million, up 48%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters